UROMITEXAN 100MG INJECTION 2ML belongs to a class of medication known as 'cytoprotectant' primarily used to prevent Hemorrhagic cystitis (a condition that causes bleeding in the urine due to the effect of anticancer agents (Ifosfamide). Our bodies degrade the anticancer drug (ifosfamide) to generate a compound (acrolein) that can injure and irritate the bladder. UROMITEXAN 100MG INJECTION 2ML decreases the risk of bladder irritation and bleeding caused by other anti-cancer drugs.

UROMITEXAN 100MG INJECTION 2ML contains 'Mesna', a chemo-protectant medicine that alters the breakdown of anti-cancer agents (Ifosfamide) found in the urine, making it less toxic. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.

UROMITEXAN 100MG INJECTION 2ML will be administered to your vein by a trained healthcare professional; hence, do not self-administer. In some cases, this medicine may cause certain side effects such as nausea, vomiting, headache, flushing (sense of warmth in the face, ears, neck, and trunk), lethargy, rash, diarrhea, light-headedness, abdominal pain, flu-like symptoms, fever, and injection site reactions. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

UROMITEXAN 100MG INJECTION 2ML is not recommended if you are allergic to it or any of its ingredients. An effective birth control measure should be taken to avoid pregnancy in women of a mother-bearing you’re your doctor may suggest regular urine and blood test while receiving UROMITEXAN 100MG INJECTION 2ML to monitor your CBC (blood cell count). UROMITEXAN 100MG INJECTION 2ML is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. It is advised to drink at least 1-2 litres of fluid daily while receiving UROMITEXAN 100MG INJECTION 2ML. This medicine should be avoided in pregnant and breastfeeding populations due to serious side effects; hence inform your doctor before administration.

UROMITEXAN 100MG INJECTION 2ML belongs to a class of medication known as 'chemoprotectant' primarily used to prevent bleeding into the urine by a particular anticancer medicine known as ifosfamide (ifosfamide-induced hemorrhagic cystitis). It also reduces the risk of inflammation and bleeding in the bladder by receiving anti-cancer medication. It contains Mesna, which works by reacting chemically with the urotoxic ifosfamide (anti-cancer medicines) metabolites, resulting in their detoxification. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.

Do not take this injection if you are allergic to UROMITEXAN 100MG INJECTION 2ML or any of its ingredients. An effective birth control method should be used to avoid pregnancy in women of childbearing age. Maintain a three-month gap between your last dose of UROMITEXAN 100MG INJECTION 2ML and your next pregnancy. Regular urine and blood test should be done while receiving UROMITEXAN 100MG INJECTION 2ML to monitor your CBC (blood cell count). It is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. This medicine is known to cause blurry vision and dizziness, so do not drive or operate machinery. 

• Regular blood and urine test are required while receiving UROMITEXAN 100MG INJECTION 2ML.
• UROMITEXAN 100MG INJECTION 2ML may interfere with enzymatic creatinine phosphokinase (CPK) activity tests that use a thiol compound (N-acetylcysteine) for CPK reactivation. This may result in a falsely low CPK level. Inform your doctor about the use of UROMITEXAN 100MG INJECTION 2ML.
• UROMITEXAN 100MG INJECTION 2ML may interfere with a certain laboratory test (for urinary ketones), possibly causing false test results. Hence inform your doctor or laboratory personnel about the use of this medicine.